Medical Knowledge Group, LLC

Medical Knowledge Group, LLC is a New York-based company that provides advanced analytics and multi-channel marketing solutions to the biopharmaceutical industry, focusing on enhancing patient outcomes and optimizing brand visibility through data-driven insights. Founded in 2004 and headquartered in New York, US, Medical Knowledge Group, LLC specializes in analytics and marketing solutions for the biopharmaceutical sector. The firm has engaged in 5 deals, with the most recent being a Buyout in April 2022 where OMERS Private Equity invested USD 36. 00 mn.

This investment has raised the total amount to USD 36. 00 mn, reflecting the company's strategic focus on analytics services. The founder's detailed history is not available. Medical Knowledge Group (MKG) specializes in advanced analytics and multi-channel marketing solutions tailored for the biopharmaceutical sector.

Their core offerings include network-mapping analytics, which allow clients to visualize and understand complex relationships within healthcare ecosystems, and patient-finding analytics, designed to identify and engage target patient populations effectively. MKG serves a diverse clientele, ranging from prominent global biopharmaceutical companies to emerging biotech firms, primarily in North America and Europe. MKG operates on a B2B transaction model, primarily engaging with clients through subscription-based services and partnership agreements. These relationships typically involve customized contracts outlining the scope of analytics services provided, duration of engagement, and associated fees.

Revenue is generated from long-term engagements, which may include milestones tied to specific performance metrics or project deliverables, with the company's flagship products central to its revenue model. Looking ahead, Medical Knowledge Group, LLC plans to expand its product offerings, including new analytics solutions tailored for evolving biopharmaceutical needs. The company aims to penetrate additional markets across Europe and Asia by 2024. The funding received from the recent Buyout will be utilized to enhance product development and market expansion efforts.